Acorda Therapeutics (ACOR) Provides Corporate Update At 32nd Annual J.P. Morgan Healthcare Conference
1/13/2014 6:58:57 AM
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg unaudited net sales for the fourth quarter of 2013 were $84 million, and unaudited AMPYRA 2013 full-year net sales were $302 million. These results are preliminary and subject to completion of the Company’s year-end audit.
Help employers find you! Check out all the jobs and post your resume.
comments powered by